Mangrove Partners
CDIOW icon

Mangrove Partners’s Cardio Diagnostics Holdings Inc Warrant CDIOW Stock Holding History

Mangrove Partners’s Portfolio CDIOW Stock Details CDIOW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-500,000
Closed -$4.96M – 380
2022
Q2 		$4.96M Hold
500,000
– – 0.24% 116
2022
Q1 		$4.94M Buy
+500,000
New +$119K 0.27% 93

Other funds holding CDIOW

Radcliffe Capital Management
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
EHP Funds Inc
EHP Funds Inc Toronto, Canada $43.6M AUM 69.08% 1-Year Est. Return
Saba Capital Management
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
Context Capital Management
Context Capital Management Lajolla, California $4.89B AUM 1.86% 1-Year Est. Return
Yakira Capital Management
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return
Polar Asset Management Partners
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.36B AUM 25.58% 1-Year Est. Return
Fifth Lane Capital
Fifth Lane Capital Austin, Texas $1.63M AUM 7.3% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Mangrove Partners's CDIOW Position: Q3 2022 in Review

Mangrove Partners sold out of Cardio Diagnostics Holdings Inc Warrant (CDIOW) in Q3 2022, closing a stake of 500,000 shares — an estimated $4.96M sold.

Mangrove Partners first reported a position in CDIOW in Q1 2022 and held it in 2 quarters. The position peaked at $4.96M in Q2 2022. 21 funds tracked by Wall St. Rank hold CDIOW as of Q3 2022.

  • Mangrove Partners reported no remaining Cardio Diagnostics Holdings Inc Warrant position as of Q3 2022 after selling out during the quarter.
  • Mangrove Partners sold 500,000 Cardio Diagnostics Holdings Inc Warrant shares in Q3 2022, an estimated $4.96M.
  • Mangrove Partners first reported a position in Cardio Diagnostics Holdings Inc Warrant in Q1 2022 and held it in 2 quarters.
  • Mangrove Partners's Cardio Diagnostics Holdings Inc Warrant position peaked at $4.96M in Q2 2022.
  • 21 funds tracked by Wall St. Rank held Cardio Diagnostics Holdings Inc Warrant as of Q3 2022.

Based on Mangrove Partners's 13F filing for Q3 2022, filed 14 Nov 2022.